JP2017500340A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500340A5 JP2017500340A5 JP2016541415A JP2016541415A JP2017500340A5 JP 2017500340 A5 JP2017500340 A5 JP 2017500340A5 JP 2016541415 A JP2016541415 A JP 2016541415A JP 2016541415 A JP2016541415 A JP 2016541415A JP 2017500340 A5 JP2017500340 A5 JP 2017500340A5
- Authority
- JP
- Japan
- Prior art keywords
- cetp modulator
- cetp
- pharmaceutical composition
- amd
- neovascularization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 claims 18
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 claims 18
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 claims 18
- 206010064930 age-related macular degeneration Diseases 0.000 claims 10
- 208000002780 macular degeneration Diseases 0.000 claims 10
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 208000030533 eye disease Diseases 0.000 claims 8
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 6
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 6
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims 6
- 229960005375 lutein Drugs 0.000 claims 6
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims 6
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims 4
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims 4
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims 4
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims 4
- 235000021466 carotenoid Nutrition 0.000 claims 4
- 150000001747 carotenoids Chemical class 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 235000012680 lutein Nutrition 0.000 claims 4
- 239000001656 lutein Substances 0.000 claims 4
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims 4
- 235000010930 zeaxanthin Nutrition 0.000 claims 4
- 239000001775 zeaxanthin Substances 0.000 claims 4
- 229940043269 zeaxanthin Drugs 0.000 claims 4
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 3
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 3
- 208000007135 Retinal Neovascularization Diseases 0.000 claims 3
- 208000017442 Retinal disease Diseases 0.000 claims 3
- 206010038923 Retinopathy Diseases 0.000 claims 3
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 3
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 3
- 201000000159 corneal neovascularization Diseases 0.000 claims 3
- 208000001309 degenerative myopia Diseases 0.000 claims 3
- 230000004340 degenerative myopia Effects 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 201000011190 diabetic macular edema Diseases 0.000 claims 3
- 208000011325 dry age related macular degeneration Diseases 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 210000001957 retinal vein Anatomy 0.000 claims 3
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 2
- 229940076783 lucentis Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 235000008210 xanthophylls Nutrition 0.000 claims 2
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000006069 Corneal Opacity Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 231100000269 corneal opacity Toxicity 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 229920001903 high density polyethylene Polymers 0.000 claims 1
- 239000004700 high-density polyethylene Substances 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13198668 | 2013-12-19 | ||
| EP13198668.9 | 2013-12-19 | ||
| PCT/EP2014/077855 WO2015091410A1 (en) | 2013-12-19 | 2014-12-16 | Cetp modulator for use in the treatment of eye disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017500340A JP2017500340A (ja) | 2017-01-05 |
| JP2017500340A5 true JP2017500340A5 (enExample) | 2018-01-25 |
| JP6539661B2 JP6539661B2 (ja) | 2019-07-03 |
Family
ID=49880487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016541415A Expired - Fee Related JP6539661B2 (ja) | 2013-12-19 | 2014-12-16 | 眼疾患の処置において使用するためのｃｅｔｐモデュレーター |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20160287537A1 (enExample) |
| EP (2) | EP3082784A1 (enExample) |
| JP (1) | JP6539661B2 (enExample) |
| KR (1) | KR20160093024A (enExample) |
| CN (1) | CN105792820A (enExample) |
| BR (1) | BR112016013923A2 (enExample) |
| CA (1) | CA2924401A1 (enExample) |
| HK (1) | HK1223827A1 (enExample) |
| MX (1) | MX2016005505A (enExample) |
| RU (1) | RU2016127357A (enExample) |
| WO (1) | WO2015091410A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2978859T (pt) | 2013-03-27 | 2018-10-04 | Hoffmann La Roche | Marcadores genéticos para previsão da capacidade de resposta à terapêutica |
| RU2703192C2 (ru) | 2014-07-30 | 2019-10-15 | Ф. Хоффманн-Ля Рош Аг | Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами |
| WO2025093436A1 (en) * | 2023-11-01 | 2025-05-08 | Newamsterdam Pharma B.V. | Treatment and prevention of age-related macular degeneration using a cetp inhibitor |
| WO2025093129A1 (en) * | 2023-11-01 | 2025-05-08 | Newamsterdam Pharma B.V. | Treatment and prevention of age-related macular degeneration using a cetp inhibitor |
| WO2025146262A1 (en) * | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Obicetrapib for use in the treatment of hemoglobinopathies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2894445B2 (ja) | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Ｃｅｔｐ活性阻害剤として有効な化合物 |
| WO2003063848A1 (en) | 2002-01-30 | 2003-08-07 | Dsm Ip Assets B.V. | Lutein/zeaxanthin for glare protection |
| PT1603553E (pt) * | 2003-03-17 | 2012-02-03 | Japan Tobacco Inc | Composições farmacêuticas de inibidores de cetp |
| US7435849B2 (en) | 2005-10-31 | 2008-10-14 | Hoffmann-La Roche Inc. | Process for the production of acid chlorides |
| US8212063B2 (en) | 2006-05-10 | 2012-07-03 | Omniactive Health Technologies Limited | Xanthophyll composition containing trans, meso-zeaxanthin, trans, R, R-zeaxanthin and trans, R, R-lutein useful for nutrition and health care and a process for its preparation |
| EP1935867A1 (en) | 2006-12-20 | 2008-06-25 | F. Hoffmann-La Roche Ag | Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid |
| WO2009129859A1 (en) | 2008-04-24 | 2009-10-29 | Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh | Compositions and methods for maintaining, strengthening, improving, or promoting eye health |
| WO2010074940A1 (en) | 2008-12-23 | 2010-07-01 | Alcon Research, Ltd. | Compositions and nutritional supplements for improving ocular health and reducing ocular inflammatory response |
| US20110004011A1 (en) | 2009-07-01 | 2011-01-06 | Declan Costello | Novel process |
| JP5676005B2 (ja) | 2010-11-04 | 2015-02-25 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオアート及びクロスカルメロースナトリウムを含む組成物 |
| BR112013018839A2 (pt) * | 2011-01-25 | 2016-09-27 | Nestec Sa | métodos e composições para o tratamento, a redução ou a prevenção de deterioração do sistema visual dos animais |
| US20120301439A1 (en) * | 2011-05-24 | 2012-11-29 | Washington University | Inhibition of choroidal neovascularization |
| ES2881671T3 (es) * | 2012-08-21 | 2021-11-30 | Opko Pharmaceuticals Llc | Formulaciones de liposomas |
-
2014
- 2014-12-16 MX MX2016005505A patent/MX2016005505A/es unknown
- 2014-12-16 CN CN201480065543.XA patent/CN105792820A/zh active Pending
- 2014-12-16 CA CA2924401A patent/CA2924401A1/en not_active Abandoned
- 2014-12-16 HK HK16112052.2A patent/HK1223827A1/zh unknown
- 2014-12-16 EP EP14812502.4A patent/EP3082784A1/en not_active Withdrawn
- 2014-12-16 EP EP19161186.2A patent/EP3524238A1/en not_active Withdrawn
- 2014-12-16 JP JP2016541415A patent/JP6539661B2/ja not_active Expired - Fee Related
- 2014-12-16 KR KR1020167016160A patent/KR20160093024A/ko not_active Withdrawn
- 2014-12-16 RU RU2016127357A patent/RU2016127357A/ru unknown
- 2014-12-16 BR BR112016013923A patent/BR112016013923A2/pt not_active Application Discontinuation
- 2014-12-16 WO PCT/EP2014/077855 patent/WO2015091410A1/en not_active Ceased
-
2016
- 2016-06-07 US US15/175,218 patent/US20160287537A1/en not_active Abandoned
-
2019
- 2019-04-03 US US16/374,045 patent/US20190224147A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ610230A (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| WO2010028088A3 (en) | Sulfur-linked compounds for treating opthalmic diseases and disorders | |
| BR112014008759A2 (pt) | tratamento de doença ocular | |
| HK1258588A1 (zh) | 用於治疗眼科疾病的化合物和制剂 | |
| EP4360709A3 (en) | Use of a vegf antagonist to treat angiogenic eye disorders | |
| RU2016127357A (ru) | Модулятор сетр для применения в лечении заболеваний глаз | |
| JP2013528607A5 (enExample) | ||
| WO2014031429A3 (en) | Liposome formulations | |
| HK1219943A1 (zh) | 用於治疗眼科疾病和障害的取代3-苯基丙胺衍生物 | |
| HK1198811A1 (en) | A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent | |
| RU2017125496A (ru) | Внутриглазная доставка биологически активных молекул с использованием ионтофореза | |
| ES2722723T3 (es) | Métodos para tratar enfermedades oculares asociadas con inflamación y proliferación vascular | |
| JP2016532658A5 (ja) | 眼病の処置のためのＮ−（４−ｔｅｒｔ−ブチルベンジル）−３−クロロ−Ｎ−［２−（４−クロロ−３−エチル−フェニル）−エチル］−２−フルオロ−５−トリフルオロメチル−ベンズアミドを含む医薬組成物の使用 | |
| JP2015083565A5 (enExample) | ||
| EP3691654A4 (en) | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF EYE SURFACE DISEASES | |
| TN2016000259A1 (en) | Salbutamol (albuterol) eye protective medicament. | |
| RU2016114724A (ru) | Применение n-(4-трет-бутилбензил)-3-хлор-n-[2-(4-хлор-3-этилфенил)-этил]-2-фтор-5-трифторметилбензамида для лечения глазных заболеваний | |
| WO2008152507A3 (en) | Compositions and methods for treating ophthalmic disorders | |
| JP2013513606A5 (enExample) | ||
| HRP20192256T1 (hr) | Uporaba kabergolina u liječenju očnih bolesti uzrokovanih povišenim čimbenikom vaskularnog endotelnog rasta | |
| Bikbov et al. | Current opportunities for the prevention of excessive scarring after glaucoma surgery using antimetabolites | |
| Ruiz-Moreno et al. | Myopic choroidal neovascularization | |
| RU2014106328A (ru) | Фармацевтические композиции, содержащие 4-бром-n-(имидазолидин-2-илиден)-1н-бензимидазол-5-амин для лечения заболеваний сетчатки | |
| JP2014521648A5 (enExample) | ||
| RU2017102407A (ru) | Применение экстракта cistanche tubulosa в получении лекарственных средств или продуктов питания для защиты клеток глаза |